We develop cutting-edge software and AI solutions for small molecule design, optimization and data analysis. Our mission is ...

Researchers used both ligand-based drug design (LBDD) and structure-based drug design (SBDD) strategies within the Chemistry42 generative chemistry engine for molecular generation. Building on the ...

The use of artificial intelligence (AI) has been increasing in scientific research and clinical applications. From determining best treatment options for cancer patients, to identifying novel ...

COSMIC (molecular conformation space modeling in internal coordinates) can provide important insights into the 3D positioning and activity of molecules to help drive decisions about drug design. While ...

This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care ...

Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix Discovery™ (https://www ...

In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. But while immunotherapy drugs offer new treatment possibilities, only about 20% ...

TOKYO, JAPAN, August 20, 2025 /EINPresswire.com/ -- Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”), a Japan-based AI drug discovery ...